There is widespread hope for curbing HIV after the United States Food and Drug Administration (FDA) approved an injectable ...

Six months of prevention -- that's how long Lenacapavir, the new drug for HIV prevention lasts.The Food and Drug Administration approved it last month, and desp ...

U.S. withdrawal of $4 billion in AIDS funding risks over 4 million deaths and 6 million new HIV infections by 2029 ...

U.S. aid cuts to global AIDS programs spark warnings of millions of deaths, as clinics close and progress unravels in ...

The U.S. Supreme Court affirmed the legality of a provision in ACA requiring insurers to cover preventative care services ...

Some poorer nations hit by cuts in HIV/AIDS funding from rich donors have boosted their own spending in response, but not ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

The Affordable Care Act will continue to provide free preventative medications to millions of people who rely on that ...